Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) ...

At the recent American Society of Gene and Cell Therapy (ASGCT) meeting, Wave Life Sciences Ltd. presented siRNAs designed to suppress expression of the liver gene inhibin subunit β E (INHBE). Human ...

GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Carrie Mckim; Investor Relations; Codexis Inc. Stephen Dilly; Chairman of the Board, President, Chief Executive Officer, Director; Codexis Inc. Stefan Lutz; Senior V ...

AbbVie and ADARx Pharmaceuticals have signed a collaboration and license option agreement to develop small interfering RNA ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

The Vallabh/Minikel lab at the Broad Institute has selected Argonaut Manufacturing Services, Inc., "Argonaut," as the drug product manufacturer for a therapeutic compound for a potential clinical ...